4yr
Does sodium oxybate inhibit brain dopamine release in humans? An exploratory neuroimaging study
Source : https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.2791
To establish in an exploratory neuroimaging study whether γ-hydroxybutyrate (sodium oxybate [SO]), a sedative, anti-narcoleptic drug with abuse potential, transiently inhibits striatal dopamine release in the human.
• Source: Human Psychopharmacology
• Conclusion/Relevance: “We did not find evidence in this sample of human subjects of a robust striatal dopamine change, as was reported in non-human primates. Our preliminary data, requiring extension, suggest that a 3g sedative SO [sodium oxybate] dose might cause slight transient inhibition of dopamine release in limbic striatum.”
• Researchers explored whether SO transiently inhibited striatal dopamine release. Of note, SO is a sedative, anti-narcoleptic drug with misuse potential.
• In the current study 10 healthy participants and one participant with narcolepsy received baseline PET scans followed by an oral sedative 3g dose of SO and two scans a week later. Plasma SO levels and drowsiness duration were measured.
• To establish in an exploratory neuroimaging study whether γ-hydroxybutyrate (sodium oxybate [SO]), a sedative, anti-narcoleptic drug with abuse potential, transiently inhibits striatal dopamine release in the human.